Nicox SA / GHO Capital Partners Llp
Exclusive Financial Advisor to Nicox for the Transfer of its European commercial operations to a newly-founded company focused on ophthalmic products in Europe.
Advised Nicox on the divestiture of their European Ophthalmics operations to GHO Capital for a total consideration of € 26m and future performance-based milestones. The commercial organization covered by this transaction marketed over 25 products directly in the top five European markets and through its distributors in over 40 other markets, and late‐stage European development programs. These assets will all be transferred to the new company. This transaction was a key step in refocusing Nicox’s resources on its R&D pipeline in ophthalmology including AC‐170 for allergic conjunctivitis, NCX 4251 for blepharitis, NCX 470 for lowering intraocular pressure in patients with glaucoma and ocular hypertension.